Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Back

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
The Journal of Antimicrobial Chemotherapy|March 29, 2011
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individualsAlessandro Schipani, Christoph Wyen, Tabitha Mahungu, et al.
Pharmacogenetics and Genomics|January 7, 2010
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphismsRuben C Hartkoorn, Wai San Kwan, Victoria Shallcross, et al.
Clinical Pharmacokinetics|September 10, 2004
Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate poolsSanjay U C Sankatsing, Patrick G Hoggard, Alwin D R Huitema, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2002
Intracellular accumulation of human immunodeficiency virus protease inhibitorsSaye H Khoo, Patrick G Hoggard, Ian Williams, et al.
Lancet (London, England)|January 26, 2002
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics studyJacques Fellay, Catia Marzolini, Emma R Meaden, et al.
The Journal of Antimicrobial Chemotherapy|February 19, 2008
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsChristoph Wyen, Heidy Hendra, Martin Vogel, et al.
Antimicrobial Agents and Chemotherapy|October 6, 2010
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearanceAlessandro Schipani, Marco Siccardi, Antonio D'Avolio, et al.
The Journal of Antimicrobial Chemotherapy|July 1, 2011
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimensChristoph Wyen, Heidy Hendra, Marco Siccardi, et al.
Clinical Pharmacology and Therapeutics|May 22, 2020
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human PharmacokineticsUsman Arshad, Henry Pertinez, Helen Box, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
The Journal of Antimicrobial Chemotherapy|March 29, 2011
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individualsAlessandro Schipani, Christoph Wyen, Tabitha Mahungu, et al.
Pharmacogenetics and Genomics|January 7, 2010
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphismsRuben C Hartkoorn, Wai San Kwan, Victoria Shallcross, et al.
Clinical Pharmacokinetics|September 10, 2004
Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate poolsSanjay U C Sankatsing, Patrick G Hoggard, Alwin D R Huitema, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2002
Intracellular accumulation of human immunodeficiency virus protease inhibitorsSaye H Khoo, Patrick G Hoggard, Ian Williams, et al.
Lancet (London, England)|January 26, 2002
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics studyJacques Fellay, Catia Marzolini, Emma R Meaden, et al.
The Journal of Antimicrobial Chemotherapy|February 19, 2008
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsChristoph Wyen, Heidy Hendra, Martin Vogel, et al.
Antimicrobial Agents and Chemotherapy|October 6, 2010
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearanceAlessandro Schipani, Marco Siccardi, Antonio D'Avolio, et al.
The Journal of Antimicrobial Chemotherapy|July 1, 2011
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimensChristoph Wyen, Heidy Hendra, Marco Siccardi, et al.
Clinical Pharmacology and Therapeutics|May 22, 2020
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human PharmacokineticsUsman Arshad, Henry Pertinez, Helen Box, et al.
Pageof 10